FDA.reportPublic FDA data

4 ML bevacizumab-tnjn 25 MG/ML Injection

RxCUI
2700735
RxNorm name
4 ML bevacizumab-tnjn 25 MG/ML Injection
Display name
4 ML bevacizumab-tnjn 25 MG/ML Injection
Full name
4 ML bevacizumab-tnjn 25 MG/ML Injection
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:12

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
a3976cf9-9edb-4ca2-9375-9bcd2e32f5b4bevacizumab-tnjn 100 MG in 4 ML Injection [PSN] · 4 ML bevacizumab-tnjn 25 MG/ML Injection [SCD] · bevacizumab-tnjn 100 MG per 4 ML Injection [SY]34These highlights do not include all the information needed to use Avzivi safely and effectively. See full prescribing information for Avzivi. Avzivi ® (bevacizumab-tnjn) injection, for intravenous use Initial U.S. Approval: 2023 Avzivi (bevacizumab-tnjn) is biosimilar to AVASTIN ® (bevacizumab)20250930